INTRODUCTION
Several treatment modalities are used to control metastatic bone pain and/or prevent skeletal related events from prostate cancer, such as radiotherapy, bisphosphonates, denosumab, samarium-153-ethylene diamine tetramethylene phosphonate (EDTMP), radium-223 dichloride therapy (Ra-223) and other bone seeking agents, however, only
Ra-223 has demonstrated improved survival , (1) (2) (3) (4) (5) (6) .
In daily clinical practice, 18F-FDG-PET/CT whole-body metabolic image is widely performed for staging, restaging, identifying responders, predicting survival (7) (8) (9) (10) and as a biomarker to assess tumor burden (11) (12) (13) (14) . One of the advantages of 18F-FDG-PET/CT imaging is the ability to objectively quantify tumor metabolism, providing prognostic and/or predictive information (15) (16) (17) .
Whole-body fluoride-PET/CT bone imaging is ideal for staging and restaging prostate cancer patients due to greater sensitivity, specificity and accuracy when compared to conventional bone scintigraphy(18).
Beyond lesion detection and staging, it is feasible to quantify skeletal tumor burden using fluoride-PET/CT. Tumor burden determined by skeletal scintigraphy have been shown to differentiate responders from nonresponders with some therapies (19).
We hypothesize that skeletal tumor burden determined by fluoride-PET/CT will be correlated with clinical outcomes in patients treated with Ra-223-223. By this determination, it may be possible to identify patients that will not respond to Ra-223 thus reducing morbidity and unnecessary costs.
The purposes of this study were to evaluate outcome after Ra-223 and the potential of fluoride-PET/CT to determine whole-body skeletal tumor burden as a prognostic biomarker of survival in patients treated with
Ra-223.
PATIENTS AND METHODS

Study Design
This study was approved by the Institutional Review Board (PA14-0848). The Waivers of Informed Consent and Authorization were granted for the retrospective analysis. We reviewed castrate resistant prostate cancer (CRPC) patients metastatic to bone, treated with Ra-223 who underwent a baseline fluoride-PET/CT.
Patient Population
389 doses were administered to 76 patients. Forty-two patients (Table 1 ) underwent a baseline Fluoride-PET/CT. Additionally, 38 of these 42 patients also underwent a baseline bone scintigraphy and another 32 patients were submitted exclusively to a bone scan (Table S1 in the Supplementary Appendix). Eleven patients (14.5%) had initial Hb levels below 10.0g/dL and received blood transfusion prior to Ra-223.
Radium-223
Radium-223 dichloride (Xofigo®, Bayer) was administered per clinical standard of care to 76 patients. Patients received between 1 and 6 doses of Ra-223 (50 kBq/kg or 1.4 µCi/kg) intravenously, at monthly intervals. 
Fluoride-PET/CT
Fluoride-PET/CT Interpretation and Quantification
Baseline Fluoride-PET/CT images were analyzed by both visual and quantitative analyses by two board-certified nuclear medicine physicians (EE, ER). Visual analysis consisted of separating into 5 categories the number of bone metastatic lesions (1-6 lesions; 6-20; 20-50; above 50 and superscan).
Quantitative interpretation (using the MIM Vista workstation) was performed on all baseline Fluoride-PET/CT images to determine wholebody skeletal tumor burden. This method is described fully in "Rohren et Once the images have been carefully analyzed, the process of calculating tumor burden is extremely fast since it is a semi-automatic measure and the physician is not required to draw VOIs on all metastasatic sites because, by establishing the threshold value SUVmax=10, the VOIs will automatically encircle the lesions and exclude all normal bone. If the amount of degenerative processes is minimal, the calculation of tumor burden takes less than five minutes.
Visual Interpretation of Other Imaging Modalities
Visual interpretation of 
Statistical Analyses
The primary end point was overall survival (OS), established from initial Ra-223 dose until date of death from any cause or last follow-up.
Secondary aims were progression free-survival (PFS) and time to bone event (TTBE). PFS was established from initial Ra-223 dose until date of objective tumor progression, death of any cause or last follow-up.
Objective tumor progression was defined as a new lesion or a lesion that increased in size (RECIST criteria) in bone, node or viscera leading to a change in current therapy or initiation of another therapy. TTBE was defined from initial Ra-223 dose until the date of a bone event (surgical intervention, spinal cord compression, pathologic fracture, bone pain or rapid lesion progression requiring immediate intervention). 
Spearman correlation assessed the amount of agreement between
Fluoride-PET/CT variables. All statistical analyses were performed using SAS 9.3 for Windows.
RESULTS
Ra-223 Doses in Relation to OS, PFS and TTBE
Ra-223 doses were completed in 44 (57.9%) patients, one patient was still undergoing Ra-223 and 31 (40.8%) patients did not complete all six doses due to either progression, hematologic toxicity, declining ECOG status by two points and/or a bone event ( Table 2 ). The mean number of doses performed was 5 (median=6 doses). The median OS time was 11.93 months (95%CI: 8.12 -censored). The median PFS was 3.68 months (95%CI:3.02-5.09), and the median TTBE could not be estimated (only 6 patients had bone events) (Tables 3 and 4 ).
There was a significant correlation between OS and the number of Ra-223 doses administered, with improved survival in patients treated with a greater number of doses, especially in patients receiving all 6
doses. The number of Ra-223 doses was an independent predictor of OS, was beneficial and reduced the risk of death.
Likewise, the risk of progression was lower in patients receiving more Ra-223 doses and PFS was higher in patients who received all 6 doses. Additionally, more Ra-223 doses was an independent predictor of PFS. There was no correlation between TTBE and the continuous number of Ra-223 doses delivered to patients.
Visual imaging analysis in relation to OS and PFS
Visual analyses were performed on 42 patients that underwent fluoride-PET/CT and on 70 patients that underwent bone scintigraphy.
Among these 70 patients, 32 underwent only bone scintigraphy while 38 underwent bone scintigraphy and fluoride-PET/CT. There were no differences in the clinical characteristics among patients that underwent only bone scintigraphy vs patients that were submitted to both scans (Table S2 in . Fluoride-PET/CT skeletal tumor burden (TLF10) with a cutoff value of 8000 discriminated survivors from non-survivors after Tc-MDP scans were not, although there was a tendency (p=0.0871) in patients with multiple metastases). Possibly we did not reach statistical significance in bone scan because of the small number of patients studied. On the other hand, Fluoride-PET/CT imaging has a high impact on management of CRPC patients when compared to body CT or MRI (27) . In addition,
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F-fluoride uptake is two-fold higher than Tc-MDP leading to improved lesion detectability (28) , (29) . Furthermore, although Fluoride-PET/CT has a higher cost, acquisition time is faster, spatial resolution higher and images may be acquired earlier (30) (31) (32) . All these factors lead to better performance of Fluoride-PET/CT to detect bone lesions and to define equivocal bone metastases (18) , (33, 34) . For example, in our patient population, among the cases where Fluoride-PET/CT detected above 20 bone metastases, bone scintigraphy detected less in 63% of the patients, although we cannot be certain if this difference of lesion detectability could impact in patient management. However, since visual analysis of Fluoride-PET/CT was not an independent predictor of OS, this supports the idea that objective skeletal tumor burden quantification is an important parameter to independently predict OS.
Bone-related laboratory parameters in CRPC patients have also been described as predictors of survival (35) . Worse survival has been associated with ALP>146U/l, pain score>3, skeletal-related events, PSA>10ng/ml, hemoglobin<12.8g/dl, visceral metastases, ECOG>1 and older age. In our patient group, we did not evaluate these parameters because our cohort was composed of patients in whom the majority of these parameters already indicated advanced disease. Among the patients with TLF10>8000, PSA levels were high in 83% (mean=211ng/ml).
Interestingly, though, four patients in our study had PSA<10 ng/ml with surprisingly high TLF10 (>8000). One patient had a PSA=2.3 ng/ml with a TLF10=22,969 while the other a PSA=7.5 ng/ml with a TLF10=25,841 both having deceased after 5 months of beginning Ra-223. ALP may reflect more accurately the extent of bone disease than PSA levels (36), however, in our study, nine patients with ALP<146U/l had TLF10>8000 and six of them deceased after an average of 6.9 months. In addition, as with other studies, visceral and nodal metastases, were also univariate predictors of OS. Since the number of Ra-223 doses in itself is a strong predictor of OS, the fact that skeletal tumor burden was an even a stronger predictor establishes Fluoride-PET/CT as an important imaging modality to guide treatment strategies, combined to laboratory results which sometimes may be misleading.
Many of the patients progressed during Ra-223 (median time to progression=3.68 months). We found that the risk of progression When comparing our results with the ALSYMPCA trial(1), we found that our median OS was lower (11.93 months vs 14.9 months, respectively), which may be due to patient characteristics. We also found that the percentage of patients with super scans (27.6% vs 9%), with ECOG status >2 (32.9% vs 13%) and the percentage of patients with less than 6 bone metastases was lower (5.3% vs 16%). Combined, these indicate a higher skeletal tumor burden in our population, which likely accounts for the reduced OS in comparison to the ALSYMPCA trial. The greater proportion of patients in our group with high skeletal tumor burden
was not based on a specific selection criteria and many patients underwent Ra-223 in a compassionate setting.
A high Gleason score normally accounts for patients having high skeletal tumor burden. It could be that the outcome we observed was related to the majority of our patients having a high Gleason score.
Maybe, in patients with lower Gleason scores (6 and 7) the outcome might have been better and a study evaluating patients only with low Gleason score is necessary to confirm our findings. However, in our study, a low
Gleason score was also related to a high tumor burden. All patients in our study were already castrate-resistant, with progression and had already 
